-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, as the situation and policy environment have changed, innovation has become a necessary means for local pharmaceutical companies to develop upward
.
In this context, the research and development and innovation of Chinese medicines have begun to be continuously promoted, and domestically-made innovative medicines have also entered the harvest stage one after another
.
According to statistics, in the first half of 2021, China has approved 21 innovative drugs, exceeding the number of innovative drugs approved by the national review in 2020, setting a new record for the review of innovative drugs in China
.
It is worth mentioning that these 21 innovative drugs include urgently needed clinical therapeutic drugs in the fields of vaccines, tumors, immune system diseases, and rare diseases
.
Among them, many are products independently researched and developed by China with independent intellectual property rights
.
In this regard, the analysis believes that China's innovative drug technology has entered a new level, and the drug research and development is also showing a new look that has been reborn
.
However, some people in the industry have pointed out that although China's drug innovation technology platform system has made great progress, a number of new drugs with independent intellectual property rights have been successfully developed, but the research and development of new drugs as a whole is still at the level of imitation and innovation, most of which are foreign The follow-up of existing new drugs is mostly me-too or me-better and other fast imitating innovative varieties, and the original innovative drugs are insufficient
.
In addition, in the case of China's weak innovation capabilities and limited resources, the problem of enterprises "getting together" to innovate is also quite serious
.
For example, statistics show that there are 225 companies in China that have carried out the internationalization of more than 200 targets, and the main trend is that the tumor field accounts for more than 60%, followed by infection, metabolism and respiratory diseases
.
It can be clearly seen from the above that tumor treatment drugs are currently the main field of new drug research and development in China
.
In addition, due to the uneven scientific research level of drug clinical trial institutions, China’s abundant disease resources have not been fully utilized in clinical trials.
Pharmaceutical companies have to carry out new drug clinical trials or bioequivalence trials (BE).
Still quite difficult
.
At the same time, due to limited clinical resources, the competition among pharmaceutical companies for clinical resources is becoming increasingly fierce.
.
How can local pharmaceutical companies develop steadily when the many drawbacks of pharmaceutical company innovation are beginning to emerge? The industry believes that pharmaceutical companies should build a professional industrial ecosystem; furthermore, strengthen international exchanges, and pharmaceutical company supervision and business models should be in line with international standards; in addition, they should target areas with development potential and accelerate the realization of corner overtaking
.
In fact, at present, domestic and foreign pharmaceutical companies attach great importance to innovation.
With continuous R&D investment, news of the approval of new drugs is expected to continue to be heard, bringing good news to the majority of patients
.
However, it should be noted that there is still a big gap between the core innovation capabilities of China's new drug creation and some foreign countries.
Therefore, the innovative drug industry should continue to make full use of its own resources, market and other advantages, and focus on major national goals and strategic needs.
Accelerate the improvement of the source supply capacity of new drug creation, break through the key common technologies, modern engineering technology, and disruptive technology in the field of new drug creation to build an independent and controllable drug innovation system
.
.
In this context, the research and development and innovation of Chinese medicines have begun to be continuously promoted, and domestically-made innovative medicines have also entered the harvest stage one after another
.
According to statistics, in the first half of 2021, China has approved 21 innovative drugs, exceeding the number of innovative drugs approved by the national review in 2020, setting a new record for the review of innovative drugs in China
.
It is worth mentioning that these 21 innovative drugs include urgently needed clinical therapeutic drugs in the fields of vaccines, tumors, immune system diseases, and rare diseases
.
Among them, many are products independently researched and developed by China with independent intellectual property rights
.
In this regard, the analysis believes that China's innovative drug technology has entered a new level, and the drug research and development is also showing a new look that has been reborn
.
However, some people in the industry have pointed out that although China's drug innovation technology platform system has made great progress, a number of new drugs with independent intellectual property rights have been successfully developed, but the research and development of new drugs as a whole is still at the level of imitation and innovation, most of which are foreign The follow-up of existing new drugs is mostly me-too or me-better and other fast imitating innovative varieties, and the original innovative drugs are insufficient
.
In addition, in the case of China's weak innovation capabilities and limited resources, the problem of enterprises "getting together" to innovate is also quite serious
.
For example, statistics show that there are 225 companies in China that have carried out the internationalization of more than 200 targets, and the main trend is that the tumor field accounts for more than 60%, followed by infection, metabolism and respiratory diseases
.
It can be clearly seen from the above that tumor treatment drugs are currently the main field of new drug research and development in China
.
In addition, due to the uneven scientific research level of drug clinical trial institutions, China’s abundant disease resources have not been fully utilized in clinical trials.
Pharmaceutical companies have to carry out new drug clinical trials or bioequivalence trials (BE).
Still quite difficult
.
At the same time, due to limited clinical resources, the competition among pharmaceutical companies for clinical resources is becoming increasingly fierce.
.
How can local pharmaceutical companies develop steadily when the many drawbacks of pharmaceutical company innovation are beginning to emerge? The industry believes that pharmaceutical companies should build a professional industrial ecosystem; furthermore, strengthen international exchanges, and pharmaceutical company supervision and business models should be in line with international standards; in addition, they should target areas with development potential and accelerate the realization of corner overtaking
.
In fact, at present, domestic and foreign pharmaceutical companies attach great importance to innovation.
With continuous R&D investment, news of the approval of new drugs is expected to continue to be heard, bringing good news to the majority of patients
.
However, it should be noted that there is still a big gap between the core innovation capabilities of China's new drug creation and some foreign countries.
Therefore, the innovative drug industry should continue to make full use of its own resources, market and other advantages, and focus on major national goals and strategic needs.
Accelerate the improvement of the source supply capacity of new drug creation, break through the key common technologies, modern engineering technology, and disruptive technology in the field of new drug creation to build an independent and controllable drug innovation system
.
